Abstract Antigen heterogeneity substantially limits the efficacy of chimeric antigen receptor–modified T (CAR T) cell therapy against solid tumors. Our study highlights the potent antitumor activity of low-dose decitabine-primed CAR T (dCAR T) cells in solid tumor models, a benefit previously confirmed in hematologic malignancies.
Fengxia Shi
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Fengxia
Contact Fengxia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack